Align Technology, Tandem Diabetes, Integra LifeSciences, Lantheus, and Inspire Medical Systems Shares Skyrocket, What You Need To Know

What Happened?

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Dental Equipment & Technology company Align Technology (NASDAQ:ALGN) jumped 6.9%. Is now the time to buy Align Technology? Access our full analysis report here, it’s free for active Edge members.
• Healthcare Technology for Patients company Tandem Diabetes (NASDAQ:TNDM) jumped 9.5%. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free for active Edge members.
• Surgical Equipment & Consumables - Specialty company Integra LifeSciences (NASDAQ:IART) jumped 9.8%. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free for active Edge members.
• Medical Devices & Supplies - Imaging, Diagnostics company Lantheus (NASDAQ:LNTH) jumped 6.4%. Is now the time to buy Lantheus? Access our full analysis report here, it’s free for active Edge members.
• Medical Devices & Supplies - Specialty company Inspire Medical Systems (NYSE:INSP) jumped 8%. Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it’s free for active Edge members.

Zooming In On Integra LifeSciences (IART)

Integra LifeSciences’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 8 days ago when the stock gained 1.7% on the news that the company received U.S. FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System, allowing its use in cardiac surgery. 

This clearance expanded the system's approved uses to include the debridement, or removal, of unwanted soft tissue during delicate procedures such as valve replacement and repair. The approval marked a significant milestone, enabling surgeons to apply the technology in these critical operations. Mike McBreen, an executive at the company, called the clearance a “pivotal expansion” and noted that the milestone strengthened Integra's ability to offer advanced surgical solutions.

Integra LifeSciences is down 47.7% since the beginning of the year, and at $12.04 per share, it is trading 54.7% below its 52-week high of $26.55 from February 2025. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $219.70.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.